MaxCyte Signs Strategic Platform License with Lyell Immunopharma

MLA

“MaxCyte Signs Strategic Platform License with Lyell Immunopharma.” Plus Company Updates, 7 July 2023. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.757953880&authtype=sso&custid=ns315887.

APA

MaxCyte Signs Strategic Platform License with Lyell Immunopharma. (2023, July 7). Plus Company Updates.

Chicago

Plus Company Updates. 2023. “MaxCyte Signs Strategic Platform License with Lyell Immunopharma,” July 7. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.757953880&authtype=sso&custid=ns315887.